Apo-Ranitidine Tablets
Ranitidine
300mg
APOTEX INC.
| Pack size | 30's (10's Blister x 3) |
|---|---|
| Dispensing mode | POM |
| Source | CANADA |
| Agent | NEW MEDICAL CENTRE |
| Retail Price | 72.50 AED |
Available as:
Indications
Apo-Ranitidine Tablets is used for:
Dyspepsia, H. pylori infection, Benign gastric and duodenal ulceration, GERD, Acid aspiration during general anesth, Prophylaxis during NSAID treatment, Stress ulceration of upper GI, Zollinger-Ellison syndrome
Adult Dose
Oral
Benign gastric and duodenal ulceration
Adult: Initially, 300 mg daily at bedtime or 150 mg bid for 4-8 wk; 300 mg bid for 4 wk may be used in duodenal ulcer to improved healing. Maintenance: 150 mg daily at bedtime. Max: 300 mg bid.
Hypersecretory conditions
Adult: Initially, 150 mg bid or tid and increased if needed. Max: 6 g daily.
Gastro-oesophageal reflux disease
Adult: 150 mg bid or 300 mg at bedtime for up to 8 wk, may increase to 150 mg 4 times daily for 12 wk in severe cases.
Dyspepsia
Adult: Chronic episodic: 150 mg bid for up to 6 wk. Short-term symptomatic relief: 75 mg repeated if necessary up to 4 doses daily. Max duration: 2 wk of continuous use at one time.
Erosive oesophagitis
Adult: 150 mg 4 times daily. Maintenance: 150 mg bid.
NSAID-associated ulceration
Adult: 150 mg bid or 300 mg at bedtime for 8-12 wk. For prevention of NSAID-associated ulceration: 150 mg bid.
Hepatic impairment: Dosage adjustment not necessary
Child Dose
Oral
Benign gastric and duodenal ulceration
Child: 1 mth to 16 yr 4-8 mg/kg daily in 2 divided doses. Max: 300 mg/day. Treatment duration: 4-8 wk. Maintenance: 2-4 mg/kg once daily. Max: 150 mg/day.
Gastro-oesophageal reflux disease
Child: 1 mth to 16 yr 5-10 mg/kg daily in 2 divided doses. Max: 300 mg/day.
Erosive oesophagitis
Child: 1 mth to 16 yr 5-10 mg/kg daily in 2 divided doses. Max: 600 mg/day.
Renal Dose
Oral:
CrCl Dosage
<50 150 mg daily at bedtime, adjust dose cautiously if necessary.Parenteral:
Individual doses may be reduced to 25 mg.
Administration
May be taken with or without food.
IV Administration
Direct injection: 50 mg diluted to ?20 mL with compatible IV infusion fluid and given over ?5 minutes (4 mL/min)
Intermittent infusion: 50 mg added to ?100 mL of compatible IV solution and infused over 15-20 minutes
Continuous infusion: 150 mg diluted in 250 mL of IV fluid and infused at 6.25 mg/hr for 24 hours
Contra Indications
Porphyria.
Precautions
Possibility of malignancy should be excluded prior to therapy as the drug may mask symptoms and delay diagnosis of gastric malignancy. Patients w/ difficulty in swallowing. Renal and hepatic impairment. Pregnancy and lactation.
Lactation: Drug crosses into breast milk; discontinue drug, use caution
Pregnancy-Lactation
Pregnancy category: B
Lactation: Drug crosses into breast milk; discontinue drug, use caution
Interactions
Delayed absorption and increased peak serum concentration w/ propantheline bromide. Ranitidine minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam and propanolol. May alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide). May reduce bioavailability w/ antacids.
Adverse Effects
Side effects of Ranitidine :
1-10%
Headache (3%)
<1%
Abdominal pain, Agitation, Alopecia, Confusion, Constipation, Diarrhea, Dizziness, Hypersensitivity reaction, Nausea, Vomiting
Frequency Not Defined
Anemia, Necrotizing enterocolitis in fetus or newborn, Pancreatitis (rare), Thrombocytopenia (rare), Pancytopenia (rare), Agranulocytosis (rare), Acquired immune hemolytic anemia (rare), Arthralgia (rare), Myalgia (rare)
Potentially Fatal: Anaphylaxis, hypersensitivity reactions.
Mechanism of Action
Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
Note
Apo-Ranitidine 300mg Tablets manufactured by APOTEX INC.. Its generic name is Ranitidine. Apo-Ranitidine is availble in United Arab Emirates.
Farmaco UAE drug index information on Apo-Ranitidine Tablets is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.